Get the Stockscreener App
12.48
2.80%
-0.36
After Hours:
12.30
-0.18
-1.44%
Emergent Biosolutions Inc stock is traded at $12.48, with a volume of 2.36M.
It is down -2.80% in the last 24 hours and up +41.50% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$12.84
Open:
$12.77
24h Volume:
2.36M
Relative Volume:
1.95
Market Cap:
$665.82M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.8455
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+28.13%
1M Performance:
+41.50%
6M Performance:
+133.71%
1Y Performance:
+37.75%
1-Day Range:
$11.62
$13.00
1-Week Range:
$9.21
$13.41
52-Week Range:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.48 | 676.67M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Emergent Biosolutions (NYSE:EBS) Shares Gap Up After Strong Earnings - MarketBeat
Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Emergent BioSolutions Raises Full-Year Revenue Guidance - MSN
Reversal indicators forming on Emergent BioSolutions Inc. stock2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Will Emergent BioSolutions Inc. benefit from macro trendsWeekly Market Report & High Accuracy Investment Signals - newser.com
Is Emergent BioSolutions Inc. stock dividend yield sustainableJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
What sentiment indicators say about Emergent BioSolutions Inc. stock2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
symbol__ Stock Quote Price and Forecast - CNN
How Emergent BioSolutions Inc. stock benefits from tech adoptionJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Emergent BioSolutions Reports Strong Q3 2025 Results - The Globe and Mail
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendations2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Will breakout in Emergent BioSolutions Inc. lead to full recovery2025 Market Trends & Low Drawdown Trading Techniques - newser.com
Will Emergent BioSolutions Inc. stock return to pre crisis levelsPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
Why Emergent BioSolutions Inc. stock remains resilientJuly 2025 Highlights & AI Driven Price Predictions - newser.com
Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results, Beats Expectations By $1.18 EPS - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Emergent BioSolutions (EBS) Earnings Transcript - The Globe and Mail
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge - MSN
Gaithersburg-based Emergent Biosolutions reports Q3 earnings - Maryland Daily Record
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Will Emergent BioSolutions Inc. stock sustain high P E ratiosJuly 2025 Gainers & Precise Buy Zone Identification - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedMarket Growth Summary & Verified Entry Point Signals - newser.com
Emergent Biosolutions: Q3 Earnings Snapshot - Stamford Advocate
Understanding Emergent BioSolutions Inc.’s price movementWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Is Emergent BioSolutions Inc. a candidate for recovery playGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Emergent Biosolutions earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates - sharewise.com
EBS Boosts Financial Outlook for Fiscal Year - GuruFocus
Emergent BioSolutions Inc Bottom Line Drops In Q3 - Nasdaq
Emergent BioSolutions Inc Reports Q3 2025 Earnings: EPS of $0.91 - GuruFocus
Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook - TradingView
Emergent BioSolutions Reports Third Quarter 2025 Financial Results - The Manila Times
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Investors in Emergent BioSolutions (NYSE:EBS) have unfortunately lost 90% over the last five years - Yahoo Finance
Chart based exit strategy for Emergent BioSolutions Inc.Watch List & High Accuracy Investment Entry Signals - newser.com
Why Emergent BioSolutions Inc. stock could rally in 20252025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):